TRAF3IP1 Antibody

What is TRAF3IP1 and what are its key cellular functions?

TRAF3IP1, also known as MIP-T3 or IFT54, is a multifunctional protein with several important cellular roles. It plays an inhibitory role on IL13 signaling by binding to IL13RA1 and is involved in suppressing IL13-induced STAT6 phosphorylation, transcriptional activity, and DNA-binding . TRAF3IP1 contributes to the assembly of protein complexes necessary for effective sorting of endosomal cargo . Additionally, it recruits TRAF3 and DISC1 to microtubules and participates in kidney development and epithelial morphogenesis . TRAF3IP1 is a negative regulator of microtubule stability, acting through the control of MAP4 levels, and is crucially involved in ciliogenesis . Studies in mouse models have demonstrated that TRAF3IP1 function is highly conserved in ciliogenesis and is important for proper regulation of several essential developmental and cellular pathways .

To maintain TRAF3IP1 antibody efficacy, follow these storage and handling guidelines:

• Store at -20°C. Most manufacturers indicate these antibodies are stable for one year after shipment when properly stored .

• For long-term storage, aliquot the antibodies to avoid repeated freeze/thaw cycles that can degrade antibody quality .

• Most TRAF3IP1 antibodies are supplied in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Some antibody formulations may also contain BSA (0.1% or 0.5%) as a stabilizer .

• When removing from storage, thaw antibodies completely before use and mix gently to ensure homogeneity.

• The antibodies should be kept on ice during experimental procedures to maintain their activity.

What controls should be included when using TRAF3IP1 antibodies for the first time?

When using TRAF3IP1 antibodies for the first time, include these essential controls:

• Positive control tissues/cells: Use samples known to express TRAF3IP1, such as HEK-293 cells for Western blot and HeLa cells for immunoprecipitation . For IHC, human breast cancer and cervical cancer tissues have been validated .

• Negative controls:

  • Primary antibody omission control

  • Isotype control using non-specific rabbit IgG

  • For genetic approaches, consider using TRAF3IP1 knockout/knockdown cells if available

• Validation across multiple techniques: Confirm findings using at least two different detection methods (e.g., WB and IF).

• Epitope competition: Pre-incubate the antibody with the immunizing peptide/protein to confirm specificity.

• Molecular weight marker: TRAF3IP1 has a calculated molecular weight of 71-78 kDa but is typically observed at 79-83 kDa in Western blots . This discrepancy may be due to post-translational modifications.

• Titration series: Test a range of antibody dilutions to determine optimal concentration for your specific experimental system, starting with the manufacturer's recommended range .

How can researchers troubleshoot weak or non-specific signals when using TRAF3IP1 antibodies?

For troubleshooting weak or non-specific signals with TRAF3IP1 antibodies:

Weak Signal Problems:

• Antigen retrieval optimization: For IHC/IF applications, test both citrate buffer (pH 6.0) and TE buffer (pH 9.0) as different epitopes may be unmasked more efficiently with different methods .

• Increase antibody concentration: If signal is weak, try a more concentrated antibody dilution while monitoring background levels.

• Extended incubation time: Consider extending primary antibody incubation to overnight at 4°C.

• Enhanced detection systems: Use amplification systems like tyramide signal amplification for IF or more sensitive ECL substrates for WB.

• Sample preparation: Ensure protein extraction methods preserve TRAF3IP1 integrity, as it interacts with cytoskeletal components.

Non-specific Signal Problems:

• More stringent blocking: Increase blocking time or try different blocking agents (BSA, milk, normal serum).

• Increase washing steps: Add more or longer washing steps between antibody incubations.

• Reduce antibody concentration: Non-specific binding may decrease with more dilute antibody solutions.

• Pre-adsorption: Pre-adsorb antibody with tissue powder from a species different from your experimental sample.

• Alternative antibody: Consider testing antibodies targeting different TRAF3IP1 epitopes, as some regions may be more prone to cross-reactivity.

How can TRAF3IP1 antibodies be used to investigate its role in ciliogenesis and developmental pathways?

TRAF3IP1 antibodies can be powerful tools for investigating ciliogenesis and developmental pathways:

• Co-localization studies: Use TRAF3IP1 antibodies with established ciliary markers (like acetylated α-tubulin and Arl13b) to examine its localization during different stages of ciliogenesis . TRAF3IP1-GFP fusion proteins have been observed in both the cilia axoneme and basal body, consistent with its role in intraflagellar transport .

• Developmental expression patterns: Employ IHC in embryonic tissues to map TRAF3IP1 expression during key developmental windows. Studies have shown TRAF3IP1 is essential for embryonic development, with Traf3ip1 mutant mice showing embryonic lethality by E13.5 .

• Live imaging of ciliary transport: Combine TRAF3IP1 antibodies with live cell imaging techniques to visualize protein dynamics during intraflagellar transport.

• Pathway analysis in Traf3ip1 mutants: Using mouse embryonic fibroblasts (MEFs) from Traf3ip1 mutant mice, researchers can investigate changes in developmental signaling pathways. Previous studies found that canonical Wnt pathway activity was largely unaffected in mutants, though specific domains in pharyngeal arches showed elevated reporter activity .

• Microtubule stability assays: TRAF3IP1 is a negative regulator of microtubule stability . Antibodies can be used to correlate TRAF3IP1 levels with acetylated microtubule levels, as Traf3ip1 mutant cells show elevated cytosolic levels of acetylated microtubules .

• Cell size regulation: TRAF3IP1 deficiency has been linked to marked increases in cell size in culture, associated with elevated basal mTor pathway activity . Antibodies can help investigate the molecular connections between TRAF3IP1, ciliary function, and cell volume control.

What is known about the interaction between TRAF3IP1 and IL-13 signaling pathways, and how can researchers investigate this relationship?

The interaction between TRAF3IP1 and IL-13 signaling presents an interesting research area with some contradictory findings:

To investigate this relationship further, researchers can:

• Co-immunoprecipitation assays: Use TRAF3IP1 antibodies for co-IP experiments to confirm physical interactions with IL-13Rα1 and assess if these interactions are context-dependent.

• STAT6 phosphorylation analysis: Compare STAT6 phosphorylation levels in response to IL-13 stimulation in wild-type versus TRAF3IP1-depleted cells using phospho-specific antibodies. The experimental protocol could include:

  • Culture cells in reduced serum medium (0.5% FBS) for 48 hours

  • Stimulate with IL-13 at various concentrations and timepoints

  • Prepare cell lysates and analyze by Western blot for total and phosphorylated STAT6

  • Compare results across multiple cell types to determine tissue-specificity

• Gene expression profiling: Analyze IL-13-responsive gene expression patterns in control versus TRAF3IP1-depleted cells to identify which downstream targets might be affected.

• Domain mapping: Create truncated TRAF3IP1 constructs to determine which domains are essential for the interaction with IL-13Rα1 and subsequent signaling effects.

• Ciliary versus non-ciliary functions: Investigate whether TRAF3IP1's effects on IL-13 signaling are dependent on its ciliary localization or represent a separate function of the protein.

How can TRAF3IP1 antibodies be used to investigate its role in human disease models?

TRAF3IP1 antibodies can be valuable tools for investigating human disease models, particularly those involving ciliopathies and related disorders:

• Senior-Loken Syndrome 9: Defects in TRAF3IP1 are a cause of Senior-Loken syndrome 9 , a rare genetic disorder characterized by nephronophthisis and retinal degeneration. TRAF3IP1 antibodies can be used to:

  • Compare TRAF3IP1 localization and expression in patient-derived cells versus controls

  • Assess ciliary formation and function in patient samples

  • Evaluate effects of specific mutations on protein-protein interactions

• Kidney disease models: Given TRAF3IP1's role in kidney development and epithelial morphogenesis , antibodies can be used to:

  • Study TRAF3IP1 expression in kidney biopsy samples from patients with various nephropathies

  • Examine ciliary abnormalities in kidney epithelial cells from disease models

  • Investigate correlations between TRAF3IP1 expression/localization and disease progression

• Cancer research: TRAF3IP1 antibodies have been validated in human breast and cervical cancer tissues . Researchers can:

  • Compare TRAF3IP1 expression levels across cancer types and stages

  • Investigate whether TRAF3IP1 dysregulation correlates with tumor progression or treatment response

  • Examine potential mechanisms linking ciliary dysfunction to cancer development

• Neurodevelopmental disorders: Given TRAF3IP1's interaction with DISC1 (Disrupted in Schizophrenia 1) , researchers can:

  • Study TRAF3IP1-DISC1 interactions in neuronal cells

  • Investigate ciliary abnormalities in models of neurodevelopmental disorders

  • Assess whether TRAF3IP1 dysregulation contributes to neurological phenotypes

What methodological approaches can be used to study TRAF3IP1 interactions with cytoskeletal components?

To study TRAF3IP1 interactions with cytoskeletal components, researchers can employ several methodological approaches:

• Co-immunoprecipitation with cytoskeletal proteins: TRAF3IP1 has been shown to interact with microtubules and tubulin . Use TRAF3IP1 antibodies for co-IP followed by Western blot analysis for:

  • α-tubulin and β-tubulin

  • MAP4 (microtubule-associated protein 4)

  • TRAF3 and DISC1, which are sequestered to microtubules via TRAF3IP1

• Microtubule co-sedimentation assays:

  • Purify tubulin and polymerize into microtubules in vitro

  • Add cell lysates containing TRAF3IP1

  • Centrifuge to pellet microtubules and associated proteins

  • Analyze pellet and supernatant fractions by Western blot with TRAF3IP1 antibodies

• Immunofluorescence co-localization studies:

  • Use double immunofluorescence with TRAF3IP1 antibodies and markers for:

    • Microtubules (α-tubulin)

    • Acetylated microtubules (acetylated α-tubulin)

    • Centrosomes (γ-tubulin)

    • Cilia (Arl13b, acetylated α-tubulin)

  • Analyze co-localization using high-resolution imaging techniques (confocal, STED, SIM)

• Live cell imaging of TRAF3IP1-cytoskeleton dynamics:

  • Generate cells expressing fluorescently tagged TRAF3IP1

  • Use live imaging to track its association with cytoskeletal elements during:

    • Cell division

    • Cell migration

    • Ciliogenesis

    • Response to cytoskeletal-disrupting drugs

• Proximity ligation assays (PLA):

  • Use TRAF3IP1 antibodies in combination with antibodies against suspected interaction partners

  • PLA will generate fluorescent signals only when proteins are in close proximity (<40 nm)

  • Quantify interaction signals in different cellular compartments or under different experimental conditions